Akeso (09926.HK) announced that it has signed an exclusive commercialization rights agreement with JUMPCAN (600566.SH), under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab Injection), which has been independently developed and approved for listing by the company, in China (excluding Hong Kong, Macau, and Taiwan).
In this cooperation, the company will receive a licensing fee of 80 million RMB, as well as milestone payments of up to 10 million RMB